Compare Harmony Gold Mining Co. (HMY) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Heron Therapeutics Inc — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Harmony Gold Mining Co. is far larger — about 147.3× Heron Therapeutics Inc's market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Heron Therapeutics Inc for 35 Days on average.
| HMY | HRTX | |
|---|---|---|
Market Cap | $10.02B | $68.01M |
Volume | 3,643,683 | 1,891,941 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $1.49 |
52-Week Low | $13.32 | $0.27 |
Typical Hold Time | 45 Days | 35 Days |
Enterprise Value | $10.07B | $174.75M |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, showing strong profitability with 29.57% net margins and robust cash flow generation. The stock appears fundamentally undervalued with a P/E of 6.02 and EV/EBITDA of 3.54, though technical indicators signal bearish momentum with the price near key support levels. Recent earnings showed mixed results with two beats and two misses, while the company continues its strategic transition toward copper production diversification.
HMY presents a compelling value opportunity given its attractive valuation multiples and strong operational performance, but faces near-term technical headwinds and execution risks in its copper expansion strategy. The bearish technical setup and cautious analyst consensus (70% hold rating) suggest patience may be warranted despite the company's solid fundamentals and record fiscal 2026 results.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
